AI Confirms Potential Reversal of Lung Scarring in Deadly Fibrosis

SAN DIEGO, CA – September 08, 2026 – For the more than 150,000 Americans battling idiopathic pulmonary fibrosis (IPF), the diagnosis is a grim countdown. With a median life expectancy of just three to five years and a relentless progression of lung scarring that suffocates the body, the current standard of care offers little more than a way to slow the inevitable. But fresh data presented at the European Respiratory Society (ERS) Congress in Barcelona suggests a potential paradigm shift is on the horizon.

San Diego-based Endeavor BioMedicines has unveiled a new analysis from its Phase 2a trial of taladegib (ENV-101), and the results are turning heads. Using a sophisticated artificial intelligence platform to scrutinize lung scans, the study revealed that taladegib may not just halt the disease's march, but could actually reverse some of its devastating structural damage. This development moves beyond simply managing decline and into the realm of tangible restoration, a critical distinction in a field starved for true breakthroughs.

A Structural Shift in Treating Fibrosis

The latest findings stem from a post hoc analysis of high-resolution computed tomography (HRCT) scans from 34 participants in the company's Phase 2a study. While previous results had already shown promising signs in preserving lung function, this deeper, AI-driven look provides the anatomical evidence to back it up. The analysis demonstrated statistically significant improvements on multiple fronts for patients treated with taladegib compared to those on placebo over 12 weeks.

Most strikingly, patients receiving taladegib experienced an average increase in lung volume of 204 mL. In stark contrast, the placebo group saw a continued decline, losing an average of 60 mL. This net difference is not just a number; it represents a meaningful recovery of lung capacity in a disease defined by its loss.

Furthermore, the AI analysis quantified the overall burden of the disease. The taladegib group saw a 2.9% mean reduction in total disease extent (TDE), a direct measure of the amount of lung tissue affected by fibrosis. The placebo group, meanwhile, saw a 1.0% increase, underscoring the drug's potential to actively reduce the fibrotic footprint. Even measures of fibrosis severity, such as the reticulovascular score (RVS), showed a statistically significant reduction in the treatment arm.

“We are encouraged by the consistency between the improvements previously observed in lung function from our Phase 2a trial and the favorable changes seen with quantitative CT assessments of lung volume and fibrosis,” said Lisa Lancaster, M.D., Chief Medical Officer of Endeavor BioMedicines. “Taken together, findings generated across multiple independent quantitative imaging approaches continue to support taladegib's potential to help patients with IPF by addressing the underlying biology of disease.”

The AI Co-Pilot: Revolutionizing Clinical Evidence

This new level of insight was made possible by Brainomix's e-Lung platform, an AI-powered imaging tool that automates the analysis of lung scans. Where traditional methods rely on functional tests like Forced Vital Capacity (FVC) or subjective radiologist interpretation, quantitative imaging provides objective, reproducible data on the lung's physical structure. It can precisely measure changes in fibrotic scarring, air trapping, and healthy lung volume, offering a more complete picture of a drug's impact.

“Quantitative CT imaging offers a powerful approach to support earlier, faster, and more informed development decisions, ultimately helping promising therapies reach patients sooner,” noted Peter George, M.B.B.S., Ph.D., a consultant pulmonologist and Senior Medical Director at Brainomix who presented the analysis.

The implications of this technological integration are profound. For decades, drug development for slow-progressing diseases like IPF has been hampered by the need for long, large, and expensive trials to detect a clinical signal. AI platforms like e-Lung can identify subtle but significant structural changes far earlier, potentially de-risking development and accelerating timelines.

“This is the future of trial design for interstitial lung diseases,” commented one independent clinical trial methodologist not involved with the study. “Instead of waiting years to see a small change in functional decline, we can now get a direct, quantifiable look at whether a drug is actually modifying the tissue. It provides a level of confidence and mechanistic proof that has been sorely lacking.”

Targeting the Engine of Scarring: The Hedgehog Pathway

What makes taladegib a potentially transformative therapy lies in its novel mechanism of action. Unlike the two currently approved IPF drugs, nintedanib and pirfenidone—which primarily slow the rate of fibrotic progression—taladegib is designed to strike at the root cause of the scarring itself. It is a potent inhibitor of the Hedgehog signaling pathway.

In healthy adults, this pathway is mostly dormant but can be reactivated after tissue injury to aid in repair. In IPF, this reactivation becomes aberrant and uncontrolled, driving the proliferation of myofibroblasts—the key cellular culprits responsible for depositing excessive scar tissue in the lungs. By binding to and inhibiting a key receptor in this pathway, taladegib effectively cuts power to this fibrosis engine, aiming to eliminate the myofibroblasts and halt the abnormal wound-healing process.

The structural improvements seen in the AI analysis lend strong support to this biological rationale. The reduction in fibrosis severity and increase in lung volume suggest the drug is not just putting the brakes on the disease but may be allowing for the resolution of some existing fibrosis, a feat current therapies cannot achieve.

Navigating a Competitive and Evolving Landscape

Endeavor’s promising data emerges at a dynamic time for IPF therapeutics. The market, long dominated by two foundational drugs, is on the cusp of new entrants. Just recently, Boehringer Ingelheim announced positive Phase III results for nerandomilast, a PDE4B inhibitor that also demonstrated an ability to slow lung function decline, positioning it as a significant future competitor.

In this increasingly crowded field, simply slowing progression may no longer be enough. The key differentiator will be the ability to offer a superior safety profile or, more importantly, a fundamentally different outcome for patients. “The bar is being raised,” noted a healthcare investment analyst. “A therapy that can demonstrate a reversal of fibrotic damage, even if modest, would be a category-defining asset. Endeavor's imaging data, if confirmed in Phase 3, points toward that potential.”

The consistency of findings across multiple quantitative imaging platforms strengthens the case for taladegib as it moves toward the next, more rigorous stages of clinical development. The next crucial step will be to replicate these structural improvements in a larger, pivotal Phase 3 trial, a challenge the company now faces with renewed, data-driven optimism.